Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients

Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients

Background/Objectives: Gemcitabine (GEM) is a gold-standard chemotherapy agent for advanced pancreatic cancer. Because of the malignant character of the disease, nearly all patients show disease progression despite treatment with GEM-based chemotherapy; therefore, second-line chemotherapy may be ben...

Full description

Bibliographic Details
Main Authors: Hisato Igarashi, Tetsuhide Ito, Terumasa Hisano, Nao Fujimori, Yusuke Niina, Mikihiko Yasuda, Toyoma Kaku, Susumu Matsuo, Takamasa Oono, Masahiro Yoshinaga, Hiroyuki Sakai, Ryoichi Takayanagi
Format: Article
Language:English
Published: Karger Publishers 2011-11-01
Series:Case Reports in Oncology
Subjects:
Pancreatic cancer
Paclitaxel
Chemotherapy
Gemcitabine failure
Second-line therapy
Online Access:http://www.karger.com/Article/FullText/334704

Internet

http://www.karger.com/Article/FullText/334704

Similar Items